Cosmo Pharmaceuticals Management
Management criteria checks 1/4
We currently do not have sufficient information about the CEO.
Key information
Giovanni Di Napoli
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | less than a year |
| CEO ownership | n/a |
| Management average tenure | 2.9yrs |
| Board average tenure | less than a year |
Recent management updates
Recent updates
Cosmo Pharmaceuticals N.V.'s (VTX:COPN) P/S Still Appears To Be Reasonable
Nov 22
Market Participants Recognise Cosmo Pharmaceuticals N.V.'s (VTX:COPN) Revenues
May 02Cosmo Pharmaceuticals' (VTX:COPN) Weak Earnings May Only Reveal A Part Of The Whole Picture
Mar 28Broker Revenue Forecasts For Cosmo Pharmaceuticals N.V. (VTX:COPN) Are Surging Higher
Mar 26Cosmo Pharmaceuticals N.V.'s (VTX:COPN) Popularity With Investors Is Clear
Dec 01Earnings Beat: Cosmo Pharmaceuticals N.V. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Jul 29We Think Cosmo Pharmaceuticals (VTX:COPN) Can Stay On Top Of Its Debt
Nov 24Cosmo Pharmaceuticals' (VTX:COPN) Solid Profits Have Weak Fundamentals
Mar 31These 4 Measures Indicate That Cosmo Pharmaceuticals (VTX:COPN) Is Using Debt Reasonably Well
Aug 02Increases to CEO Compensation Might Be Put On Hold For Now at Cosmo Pharmaceuticals N.V. (VTX:COPN)
May 20Cosmo Pharmaceuticals (VTX:COPN) Seems To Use Debt Quite Sensibly
Apr 03When Can We Expect A Profit From Cosmo Pharmaceuticals N.V. (VTX:COPN)?
Mar 07CEO
Giovanni Di Napoli (50 yo)
less than a year
Tenure
Mr. Giovanni Di Napoli is Chief Executive Officer and Director of Cosmo Pharmaceuticals N.V. from May 24, 2024. He was President of Gastrointestinal at Medtronic plc. He is an accomplished leader with an e...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 18.9yrs | €1.16m | no data | |
| Executive VP of Corporate Governance | less than a year | no data | no data | |
| Chief Executive Officer & Director | less than a year | no data | no data | |
| Founder & Non-Executive Director | 18.9yrs | €400.00k | no data | |
| Chief Financial Officer | less than a year | no data | no data | |
| Chief Operating Officer | 3.9yrs | no data | no data | |
| Qualified Person & Technical Director | 13.3yrs | no data | no data | |
| Chief Scientific Officer | 2.7yrs | no data | no data | |
| Head of Investor Relations | 2.9yrs | no data | no data | |
| Chief People Officer | 3.9yrs | no data | no data | |
| Chief Manufacturing Officer | 27.9yrs | no data | no data | |
| President of Cosmo Intelligent Medical Devices | no data | no data | no data |
2.9yrs
Average Tenure
52yo
Average Age
Experienced Management: COPN's management team is considered experienced (2.9 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 18.9yrs | €1.16m | no data | |
| Executive VP of Corporate Governance | less than a year | no data | no data | |
| Chief Executive Officer & Director | less than a year | no data | no data | |
| Founder & Non-Executive Director | 18.9yrs | €400.00k | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Non-Executive Director | 12.7yrs | €128.79k | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Non-Executive Director | less than a year | no data | no data | |
| Non-Executive Director | less than a year | no data | no data |
0.6yrs
Average Tenure
61yo
Average Age
Experienced Board: COPN's board of directors are not considered experienced ( 0.6 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 09:12 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Cosmo Pharmaceuticals N.V. is covered by 14 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Laura Pfeifer-Rossi | Bank am Bellevue |
| Silvia Schanz | Bank Vontobel AG |
| Laura Hindley | Berenberg |